$200,000 cash prize pool; 12 million OnSolo credits (valued at $300,000) Plus, global distribution opportunities and dedicated promotional support 116 award places; Up to $100,000 for one winning project

Make It Short. Make It Global The OnSolo × ReelShort Global Short Drama Competition is officially open! $200,000 cash prize pool; 12 million OnSolo credits (valued at $300,000) 116 award places; Up to $100,000 for one winning project！

A professional image model that doesn't cost like one. $0.024 per 2K image. Meet Hy Image3.5 preview. > up to 5 reference images in, and the meter only runs on what comes out >multi-turn editing with earlier edits in context > text, layout and 2K consistency, the parts that break posters and UI mocks Free for two weeks in @OnSoloAI and @Miora_Design . API: Previews exist to get corrected, tell us what's off and it goes into the next version.

Genie Ontology works on day one, but the quality of its answers improves as the business context underneath it gets stronger. A practical path is to build that context layer by layer: ↳ Strengthen the data foundation ↳ Enrich metadata ↳ Model critical business semantics ↳ Curate trusted assets ↳ Govern access ↳ Evaluate and improve over time You don’t need to tackle everything at once. Start with one high-value domain, harden the definitions and sources that matter most, then expand as you learn. Read the guide:

GI Oncology saw some major changes in NCCN this week. 🔥 🧬 1. Daraxonrasib is officially in the pancreatic cancer guidelines You knew it was coming, now it is here. Preferred, Category 1. Use it. RASolute-302 in previously treated metastatic PDAC: OS: 13.2 vs 6.6 months, HR 0.40 PFS: 7.3 vs 3.5 months, HR 0.45 Subsequent therapy, and importantly it also sneaks into 1L as “useful in certain circumstances,” although only 2B for fit patients (but still there, YAY). So no, we are not throwing FOLFIRINOX/NALIRIFOX in the garbage (yet). But a RAS inhibitor is now a standard treatment for pancreatic cancer. 🔵 2. Zanidatamab + tislelizumab in NCCN for HER2+ GEA Zanidatamab + tislelizumab + chemo vs trastuzumab + chemo: PFS: 12.4 vs 8.1 months, HR 0.63 OS: 26.4 vs 19.2 months, HR 0.72 NCCN now lists zanidatamab-based therapy as Preferred first-line treatment. But… Category 2A. Why? 2A still means uniform NCCN panel consensus (≥85%) that the treatment is appropriate (so yes, you should be using this for these patients), but officially reflects lower-level evidence than Category 1. Except HERIZON was a randomized phase III trial with positive outcomes. So why 2A? Two informed guesses. 1. No US patients were enrolled. It was a large international study, and frankly the incredibly diverse patients I see in NYC probably look more like a global trial population than many historical US trials. 2. The control arm didn't include PD-1. HERIZON compared against trastuzumab + chemo, while our current US standard for PD-L1 CPS ≥1 is pembrolizumab + trastuzumab + chemo. But before we poo-poo HERIZON because of the comparator, let's look at what those studies actually achieved. KEYNOTE-811, CPS ≥1: PFS 10.9 months OS 20.1 months HERIZON: PFS 12.4 months OS 26.4 months Of course, no one would ever compared across trials. 😅 But HERIZON's own trastuzumab/chemo control arm had an OS of 19.2 months. This wasn't a control arm falling over. To me, these data show a real advance in HER2 therapy. If you’re using it, do watch for the diarrhea. NCCN specifically recommends antidiarrheal prophylaxis with zanidatamab and avoiding bolus 5-FU. Grade ≥3 diarrhea was 24.8% with the quadruplet but can be controlled and is only during the first few treatments. 3. And very briefly, MATTERHORN FLOT + durvalumab was upgraded 2B → 2A for PD-L1 <1 and diffuse-type EGJ adenocarcinoma. Overall MATTERHORN: 2-year EFS 67.4% vs 58.5%, HR 0.71, with pCR 19.2% vs 7.2%. Love seeing forward progress in GI Oncology. @TheGutOncLab @OncoAlert @Onco_Nexus @oncodaily